Pentostatin treatment combinations in chronic lymphocytic leukemia

Nicole Lamanna, Neil E. Kay

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


There have been great strides in the treatment of chronic lymphocytic leukemia (CLL). Fludarabine is the most widely studied of the purine analogs that have significantly impacted the treatment of this disease. Pentostatin has also been shown to have clinical activity in CLL and appears to be less toxic than its fludarabine counterpart, which may offer some important advantages. This text will review the rationale and more recent clinical trial results for pentostatin-based combinations in both the upfront and relapsed treatment setting for patients with CLL. Attention to the frequency of response, ability to achieve minimal residual disease, and toxicity from these approaches will be emphasized. Where feasible, we will also compare the impact of pentostatin-based treatments to fludarabine-based combinations in CLL. In addition, this review will update the latest relevant work presented at the recent 2008 American Society of Hematology meeting and future directions in regard to the continued study of pentostatin-based combinations will be discussed.

Original languageEnglish (US)
Pages (from-to)386-392
Number of pages7
JournalClinical Advances in Hematology and Oncology
Issue number6
StatePublished - Oct 5 2009


  • CLL
  • Clinical trials
  • Pentostatin
  • Toxicity

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Pentostatin treatment combinations in chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this